Home Blog Page 2499

Wel-Bloom and New-In to Exhibit at Vitafoods Asia 2025, Advancing Sustainable Innovation in Nutrition

By
Advertorial Desk
-

NEW TAIPEI CITY, Sept. 8, 2025 /PRNewswire/ — As a leader of jelly supplements, Wel-Bloom Biotech will join its affiliated company New-In in exhibiting at Vitafoods Asia 2025, held in Bangkok, Thailand from September 17 to 19, 2025. The showcase will feature a variety of technologies and Taiwan-sourced ingredient applications, presenting an upgraded one-stop CDMO service that reflects the group’s commitment to both nutritional innovation and sustainable manufacturing.

Having developed health supplements for brand partners in over 60 countries worldwide, Wel-Bloom is recognized for its high level of customization in flavor, texture, and formulation. This year, the company introduces its innovative NutriOne™ oil-based jelly technology, which effectively addresses key challenges of oil-based ingredients such as stability, odor, and consumption convenience—significantly enhancing product marketability.

Wel-Bloom offers one-stop supplement CDMO services with expert customization in flavor, texture, and formulation.
Wel-Bloom offers one-stop supplement CDMO services with expert customization in flavor, texture, and formulation.

Wel‑ROS6® black roselle extract is a highlight ingredient at this year’s exhibition. Co-developed by Wel-Bloom in partnership with Taiwanese agricultural specialists, this roselle extract is rich in anthocyanins and offers outstanding stability and nutritional value, making it ideal for a wide range of product applications. Through Wel-Bloom’s efficacy platform, the ingredient’s health potential can be systematically explored and supported by scientific data, enhancing its credibility in product development. In July, Wel‑ROS6® was introduced at a trend seminar hosted by a well-known nutritionist and quickly garnered strong interest within Taiwan’s nutrition community. The showcase will also feature other signature Taiwan-origin ingredients such as Wel‑EGT® and ZiDe‑T™, reflecting Wel-Bloom’s strategic focus on functionally validated ingredient innovation.

In addition, three newly developed ingredients will make their international debut at the show:

  • Wel‑βoost™ – supports immune health
  • Fit‑Da™ – promotes healthy weight management
  • Z3ELAX™ – designed for stress relief and sleep support

All three were formulated by Wel-Bloom and are exclusively distributed worldwide by New-In, reflecting the group’s R&D-to-market integration and rapid application capabilities.

Vitafoods Asia 2025 will take place at the Queen Sirikit National Convention Center in Bangkok. Wel-Bloom warmly invite partners and industry professionals to visit Booth J25 to explore new possibilities in nutrition innovation.

Forvis Mazars Partners with EcoOnline in Singapore, Strengthening Sustainability & ESG Reporting

By
Advertorial Desk
-

LONDON / SINGAPORE – Media OutReach Newswire – 8 September 2025 – Forvis Mazars, a leading international audit, tax and advisory firm, today announced a strategic partnership in Singapore with EcoOnline, a global provider of safety and sustainability software. This partnership will further enable Forvis Mazars and its clients to adopt EcoOnline’s advanced environmental, social, and governance (ESG) solution, enhancing the firm’s own suite of sustainability reporting and assurance services with a powerful, science-based technology tool.

This partnership is launched as Singapore companies have an extended timeline to navigate mandatory climate-related reporting standards from the Singapore Exchange (SGX) and the Accounting and Corporate Regulatory Authority (ACRA). It also provides a timely solution for businesses aligning with the ambitious goals of the Singapore Green Plan 2030 and its target of net-zero by 2050.

EcoOnline’s ESG software will directly support and enhance Forvis Mazars’ established sustainability services by providing clients with a robust tool for data management, calculation and reporting. With the timeline extended for most non-Straits Times Index (STI) companies, organisations can evaluate gaps and build robust capabilities and capacity to manage reporting challenges.

Key Forvis Mazars services to be augmented by the solution include:

  • Framework reporting advisory: Streamlining the collection and analysis of ESG data for global and regional reporting, fully aligned with Corporate Sustainability Reporting Directive (CSRD), Global Reporting Initiative (GRI), Task Force on Climate-related Financial Disclosures (TCFD) and other leading frameworks and standards
  • Climate risk analytics: Eliminating manual work around researching physical risk exposure and impact assessment with location-specific, science-based data for decision making
  • Carbon accounting: Utilising the solutions independently verified calculation engine to ensure Scope 1, 2, and 3 emissions are credible to facilitate clients’ decarbonisation journey
  • Forecasting: Providing audit-ready, science-based outputs and dynamic scenario modelling, auto-updated with live data, to help organisations confidently plan their emissions reduction strategies and evaluate multiple what-if scenarios
  • Sustainability assurance: Providing a clear, auditable trail of data that strengthens the integrity of information for both internal governance and external assurance.

EcoOnline’s ESG and Sustainability solution was designed by environmental scientists, including a Nobel Peace Prize laureate and is recognised as a Leader in the 2025 Verdantix Green Quadrant for ESG. Built for enterprise-grade complexity, based on standards such as the GHG Protocol, ISO 14064-1 and PAS 2050, it provides transparent, accurate reporting that helps organisations meet goals, reduce costs and increase overall performance.

“Although ACRA and SGX Reg Co have recently announced extended timelines for non-STI listed companies to adapt climate related disclosure, it is imperative for organisations not to pause, but take the opportunity to build capabilities to support our national net-zero agendas and be ready for mandatory assurance to improve investor confidence,” said Lai Kee Yin, Partner in Technology, Digital & Sustainability Consulting at Forvis Mazars. “We consistently hear from clients that their biggest challenge is moving beyond narrative-based reports to produce auditable, investment-grade data. Having used EcoOnline’s solution ourselves, we have firsthand confidence in its science-based approach.”

“We’re delighted to welcome Forvis Mazars Singapore into our global partner community,” commented Sean Flynn, Regional Sales Director at EcoOnline. “Their depth of sustainability expertise and advisory experience makes them a highly valued partner as organisations in Singapore – a hub for global headquarters in Asia – work to deliver on the ambitions of the Green Plan 2030 and the path to net zero by 2050. With Forvis Mazars’ insight and EcoOnline’s connected safety and sustainability suite, we can provide organisations with the tools and guidance they need to accelerate their sustainability journey. Together, we look forward to supporting businesses that share our vision of a safer, more sustainable world.”

The partnership also focuses on market awareness through educational initiatives in Singapore, including training and knowledge-sharing sessions, to help companies better understand and leverage the solution.

The integrated ESG and sustainability solution from Forvis Mazars and EcoOnline is now available to clients in Singapore.

Hashtag: #ForvisMazars #ForvisMazarsSingapore #EcoOnline #Sustainability #GreenTech #EcoSolutions #Partnership #ESGReporting #Compliance




The issuer is solely responsible for the content of this announcement.

Forvis Mazars in Singapore

Forvis Mazars Group SC is an independent member of Forvis Mazars Global, a leading professional services network. Operating as an internationally integrated partnership in over 100 countries and territories, Forvis Mazars Group specialises in audit, tax and advisory services. The partnership draws on the expertise and cultural understanding of over 40,000 professionals across the globe to assist clients of all sizes at every stage in their development. Forvis Mazars in Singapore is part of the Forvis Mazars Group. Our clientele benefits from the combined expertise of 400+ Singapore-based professionals and our international team.

EcoOnline
EcoOnline delivers uncomplicated environment, health and safety (EHS), chemical management and ESG/sustainability technology solutions to forward-thinking leaders. Safeguarding your entire workforce, from frontline employees to lone workers and contractors, EcoOnline’s always-on solutions support your organisation through everyday operations and moments of emergency and crisis alike. Our connected suite of SaaS software enables over 11,000 businesses to protect their people and the planet by ensuring compliance, risk visibility and mitigation, operational predictability and long-term resilience. Backed by an unwavering commitment to customer success, EcoOnline’s software is powerful yet simple to use – built on decades of real-world expertise, data and insights.

Visit to immediately and positively impact your workplace safety and sustainability.

Alpro Launches Prof. Slow to Help Malaysians Make Rice Kinder to Blood Sugar

By
Advertorial Desk
-

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 8 September 2025 – Nutritionists and Dietitians of Alpro Pharmacy, Malaysia’s largest prescription pharmacy chain, has introduced a clinically developed dietary solution to address one of the nation’s most pressing health challenges: diabetes. Known as Prof. Slow Smart Fibre, the functional powder lowers the glycaemic index (GI) of rice by up to 38%, allowing families to continue enjoying their staple food while keeping blood sugar levels more stable.

(From Left: Ms. Michelle Zhang (Director of Overseas Business of Prof. Slow); Pharmacist Lim En Ni (Chief Pharmacist, Engagement Director of Alpro Pharmacy); Mr. Jim Li (Chief Operation Officer of Prof. Slow); Mr. Eric Huang (Chief Executive Officer of Prof. Slow); Dr. Wong Poh Shean (Consultant Endocrinologist in Internal Medicine at Hospi019-906 7923tal Tuanku Ja’afar Seremban, Vice President of Diabetes Malaysia Negeri Sembilan); Mr Terry Lee (Chief Executive Officer of BMS Organics); Ms Tan Bee Lang (Manager of Corporate Sales & Training Department of BMS Organics); Ms Chua Kai Jia (Professional Care and Development Manager of Alpro Pharmacy); Pharmacist Low Swee Siong (Chief Executive Officer of Alpro Pharmacy)
(From Left: Ms. Michelle Zhang (Director of Overseas Business of Prof. Slow); Pharmacist Lim En Ni (Chief Pharmacist, Engagement Director of Alpro Pharmacy); Mr. Jim Li (Chief Operation Officer of Prof. Slow); Mr. Eric Huang (Chief Executive Officer of Prof. Slow); Dr. Wong Poh Shean (Consultant Endocrinologist in Internal Medicine at Hospi019-906 7923tal Tuanku Ja’afar Seremban, Vice President of Diabetes Malaysia Negeri Sembilan); Mr Terry Lee (Chief Executive Officer of BMS Organics); Ms Tan Bee Lang (Manager of Corporate Sales & Training Department of BMS Organics); Ms Chua Kai Jia (Professional Care and Development Manager of Alpro Pharmacy); Pharmacist Low Swee Siong (Chief Executive Officer of Alpro Pharmacy)

“Health isn’t about forcing compliance, it’s about making better options available,” said Dietitian Chua Kai Jia, Professional Care & Development Manager at Alpro Pharmacy. “With Prof. Slow, Malaysians don’t have to choose between their culture and their health. We’re giving them a way to enjoy rice while managing glucose levels more effectively.”

The launch comes at a critical time for public health in Malaysia. According to the National Health and Morbidity Survey (NHMS) 2023, 15.6% of Malaysian adults, roughly 1 in 6 are now living with diabetes. Earlier projections warned that by 2025, over 7 million Malaysians (or 31.3% of adults) would be affected, a figure that now appears alarmingly close. Beyond its medical toll, the economic impact is severe: a joint report by the Ministry of Health and the World Health Organization estimates RM9.65 billion in annual direct healthcare spending on diabetes, cardiovascular disease, and cancer, with an additional RM8.91 billion lost in productivity and absenteeism.

Diet remains a key contributor to this trend. White rice, noodles, sweetened beverages, and refined carbohydrates dominate Malaysian meals, while fibre intake remains critically low. Over 84.6% of adults consume less than the WHO’s recommended 25 grams of daily fibre, with average intake between just 6.9 — 7.8 grams. Meanwhile, over 64% of Malaysians eat at least one meal daily outside the home, where GI values and nutritional transparency are rarely available, making blood sugar management even more difficult.

Healthcare professionals have underscored the importance of complementary solutions alongside medication. “With 1 in 6 Malaysians now living with diabetes, it is crucial to combine lifestyle changes with prescribed medications,” said Dr. Wong Poh Shean, Consultant Endocrinologist in Internal Medicine at Hospital Tuanku Ja’afar Seremban and Vice President of Diabetes Malaysia (Negeri Sembilan). “In order to ensure the sustainability of good dietary habits, practical approaches to food are essential. This will allow patients to continue to enjoy staple foods like rice.”

Prof. Slow is part of Alpro’s wider commitment to preventive healthcare through nutrition. The range also includes W-Cookies, a fibre-enriched snack at just 50 kcal per serving, and Chia Seed Peanut Butter Jam, a natural spread made with no added salt, sugar, or artificial flavouring. While not intended as medical treatment, these products are designed to support healthier food routines, particularly for individuals managing blood sugar or reducing glycaemic load.

Together, these solutions address Malaysia’s nutritional gaps, making balanced living both accessible and sustainable. Prof. Slow products are now available at all Alpro Pharmacy, Alpro Sugiスギ Pharmacy, and BMS Organics.

Hashtag: #Alpro

The issuer is solely responsible for the content of this announcement.

About Alpro Pharmacy

With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio and Alpro Baby, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals.

Serving more than 3 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia.

For more information, please visit .

BLUETTI Launches 9.9 Mega Sale on Lazada: Affordable Backup for Every Home

By
Advertorial Desk
-

MANILA, Philippines , Sept. 8, 2025 /PRNewswire/ — BLUETTI, a technology pioneer in clean energy, is launching its 9.9 Mega Sale on Lazada from September 8th to 18th, with up to 70% off, flash deals, and exclusive gifts. The newly-released Elite series provide next-level backup power with enhanced performance, efficiency, and portability. These offerings give Filipinos an affordable way to prepare for power outages triggered by ongoing monsoon rains and typhoons.

BLUETTI
BLUETTI

New Elite 100 V2: Keep Life Going During Outage

Power outages throw life into a mess—freezers thaw and fans stop. The Elite 100 V2 restores order with 1,800W output (2,700W surge) packed in a 35% more compact casing. 11 versatile outlets cater to all essentials, including phones, fridges, and electric fans for uninterrupted comforts. A 1,024Wh LiFePO4 battery offers about 9 hours of TV time. Fueled by the latest TurboBoost tech, charging is faster than ever: 0-80% in 45 minutes from the wall or a full solar charge in just 70 minutes.

New Elite 200 V2: Extended Backup for Bigger Loads

For households or small stores that need stronger backup, the Elite 200 V2 pumps out 2,600W power for heavy-duty microwaves and commercial coolers while being 40% smaller than the peers. Its self-comsumption drops to an industry low, allowing the 2073.6Wh capacity to power a 40W fan for over 32 hours, or a 100W fridge for 14 hours. Built with automotive-grade LiFePO₄ cells, it promises up to 17 years of service life—12 times longer than the average.

BLUETTI EB3A: Grab-and-Go Everyday Power

Flooding often forces families to evacuate on short notice. The 4.6kg EB3A provides critical mobile power (600W/268Wh) in a pinch. It has 9 outlets to keep everyone’s phones charged and the network operational. A built-in LED light with an SOS mode adds convenience during emergencies.

Extra Perks

BLUETTI is sweetening the sale with exclusive freebies: a carrying pack or Decathlon backpack with the AC70 and Elite 100 V2, plus a trolley for AC200L and Elite 200 V2 buyers (limited availability). Customers can also join BLUETTI philippines social media giveaway to win an AC2A. Explore the BLUETTI Lazada store now.

About BLUETTI

Founded in 2009, BLUETTI has grown into a leading clean energy brand with innovative portable power stations, solar panels, and home storage systems. Serving over 4 million customers in 110+ countries, BLUETTI continues to make sustainable, reliable power accessible to households worldwide.

Korean Early Childhood Playgym TuniTuni Opens First Center in Thao Dien, Ho Chi Minh City

By
Advertorial Desk
-

HO CHI MINH CITY, Vietnam, Sept. 8, 2025 /PRNewswire/ — TuniTuni, a leading Korean early childhood playgym, has officially opened its first direct-operated center in Thao Dien, Ho Chi Minh City on September 8.

The entrance of the new TuniTuni center in Thao Dien, Ho Chi Minh City.
The entrance of the new TuniTuni center in Thao Dien, Ho Chi Minh City.

The TuniTuni program is designed to nurture not only children’s physical development but also their cognitive and social-emotional growth. Its unique curriculum combines storytelling, movement, and imaginative play, with fresh themes introduced weekly to keep children engaged and inspired.

TuniTuni is already a trusted name in South Korea, where one in six children has experienced its programs. Building on this strong foundation, the brand chose Thao Dien — a lively community known for young families and international schools — as the location for its first center in Vietnam.

To celebrate the opening, families who enroll by September 21st will receive a 15% discount.

TuniTuni has also gained strong momentum in other international markets. In Hong Kong, high demand has led to waiting lists of more than 300 children, with a third center set to open this November. In Malaysia, the brand recently launched its second center in Bukit Jalil. In the U.S., a newly opened center in Fort Lee, New Jersey earned an average parent satisfaction rating of 9.8 out of 10 during pilot classes.

With the opening of its first center in Ho Chi Minh City, TuniTuni looks forward to welcoming local families in Thao Dien and becoming part of the community.

Contact:
TuniTuni Thao Dien
Thao Dien Green Mall, 2F, 192 Nguyễn Văn Hưởng, Thảo Điền, Thủ Đức, Hồ Chí Minh 700000
Instagram: @tunituni_vn

About TuniTuni Vietnam

Founded in Korea in 2003, TuniTuni is an early childhood playgym program that blends storytelling, physical activity, and imaginative play to support children’s holistic development. Over the past two decades, TuniTuni has grown into a trusted brand in Korea, where one in six children has experienced its programs.

Building on this success, TuniTuni Vietnam aims to bring the same joyful and purposeful learning experience to families in Ho Chi Minh City. With its first direct-operated center now open in Thao Dien, TuniTuni Vietnam is committed to providing young children with a safe, engaging, and development-focused environment.

Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines

By
Advertorial Desk
-

SHANGHAI, Sept. 8, 2025 /PRNewswire/ — Epigenic Therapeutics (“Epigenic”), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry. This round of funding will primarily support the ongoing clinical development of EPI-003 for chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment. Additionally, the fund will accelerate the advancement of multiple preclinical programs and further strengthen the company’s technology platforms, providing strong momentum for Epigenic’s deep commitment to innovation of epigenetic medicine.

As a pioneering biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, Epigenic has consistently remained at the forefront of the industry. Its proprietary EPIREG™ technology platform enables efficient, durable, and specific silencing of target genes through precise DNA methylation and histone modification. Unlike traditional gene-editing tools that rely on DNA cleavage, EPIREG™ offers a safer and revolutionary therapeutic approach for patients with chronic diseases, effectively mitigating safety concerns associated with conventional gene editing. 

Notably, Epigenic has independently developed EpiTax™, an in-vivo LNP delivery platform, to precisely deliver EPIREG™ tools to the liver as well as multiple extrahepatic organs. This further expands the application scope of EPIREG™ across a broader range of disease areas, further enhancing Epigenic’s technology portfolio and competitive edge. 

In addition, the AIAID™ platform developed by Epigenic empowers the molecular design, target selection, and precise modulation of epigenetic medicine. The platform is equipped with a self-developed foundational model for epigenetics, providing precise core data and algorithm support. The multi-agent collaborative virtual lab autonomously performs tasks such as target discovery, target investigation, accessibility prediction, sgRNA design and evaluation, virtual epigenetic modulation, and multi-omics analysis. Furthermore, the platform utilizes AI-driven de novo protein design and AI-directed evolution to accelerate the discovery, iteration, and optimization of EPIREG™. 

“We are deeply grateful for the trust and support from both new and existing shareholders,” said Dr. Bob Zhang, Co-founder & CEO of Epigenic Therapeutics. “Since our inception, we have remained focused on advancing epigenetic modulation technologies and have achieved remarkable progress in just a few years. We will continue to drive the clinical development of our core pipelines to deliver safe and effective therapies to patients as soon as possible.” 

“Epigenetic drug development is a highly promising field, and Epigenic has demonstrated outstanding technological advantages and growth potential,” said Mr. Zhihua Yu, Chairman of Lapam Capital. “The combination of its EPIREG™ platform and EpiTax™ delivery system provides a unique solution for disease treatment. With this financing, we believe Epigenic will achieve further breakthroughs in clinical development and technological innovation, solidifying its leadership in epigenetics and bringing transformative therapies to patients worldwide.” 

About Epigenic Therapeutics

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next-generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering genetic technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatments for metabolic, cardiovascular, viral hepatitis, ocular and autoimmune diseases, etc. For more information, please visit www.epigenictx.com 

About Lapam Capital 

Headquartered in Beijing, Lapam Capital is a leading venture capital firm specializing in the biomedical sector in China. The frim currently manages five RMB funds and one USD fund, with total assets under management exceeding RMB 10 billion. Notably, it is the only biomedical investment institution that has received funding from China’s two most prominent RMB limited partners (LPs)-the National Social Security Fund and the National SME Development Fund. Lapam Capital focuses on innovative pharmaceuticals and cutting-edge medical devices, with a stategic emphasis on early-stage and early-to-mid-stage enterprises. To date, the firm has invested in a total of 200 enterprises, including over 160 innovative drug companies and more than 30 innovative medical device companies. Lapam Capital’s leadership team includes multiple partners with over 20 years of experience in both international and domestic biopharmaceutical R&D and management. This enables the firm to provide comprehensive value-added services to its portfolio companies.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since its establishment, it has invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

To date, Qiming Venture Partners has backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. For more, please visit www.qimingvc.com

About OrbiMed

OrbiMed is a leading global healthcare investment firm, with over $17 billion in assets under management across a range of private equity funds, public equity funds, and private credit/royalty funds. It invests across the healthcare industry, from start-ups to large multinational corporations. OrbiMed’s team of over 100 scientific, medical, investment, and other professionals are based in key markets around the world. For more information on OrbiMed, please visit www.orbimed.com

About IFSC

Founded in 2017, IFSC is an investment institution focused on the life sciences. Guided by the philosophy of “value investing driven by basic science,” it seeks out “scientist-entrepreneurs.” The firm continuously targets unmet clinical needs in order to advance human health. To date IFSC has managed more than twelve funds, pursues a high-win-rate strategy, and has seen six of its ten historical healthcare investments go public through IPOs.

WSPN Completes Acquisition of Aplauz NL B.V.

By
Advertorial Desk
-

TORTOLA, British Virgin Islands, Sept. 8, 2025 /PRNewswire/ — Worldwide Stablecoin Payment Network (WSPN), a leading global digital payments company, today announced the successful acquisition of Aplauz NL B.V., a licensed Dutch Electronic Money Institution (EMI) and subsidiary of Aplauz Financial Services Ltd. The transaction was approved by De Nederlandsche Bank (DNB) in June 2025 and finalized in July 2025.

The acquisition underscores WSPN’s commitment to building a global presence while advancing compliant stablecoin payment ecosystems across key markets. It reflects WSPN’s determination to drive the standardization of stablecoin services and to broaden its reach into diverse real-world applications, helping accelerate the development of future financial infrastructure.

Executive Statements

“The acquisition of Aplauz NL B.V. strengthens our European presence and accelerates our mission to pioneer transparent and inclusive digital payments,” said Raymond Yuan, Founder & CEO at WSPN. “With Aplauz’s established platform and team, we will explore broader market opportunities in productizing stablecoin use cases, delivering innovative next-generation payment network solutions to more partners and users.”

“We are delighted to complete this next step in our journey,” said Goran Abramović, Director of Aplauz Financial Services Ltd. “The successful sale of our Dutch operations to WSPN highlights the strength of the Aplauz platform and its relevance in today’s evolving digital payments landscape. We are confident that WSPN will build on this foundation and unlock exciting opportunities for Aplauz NL B.V.”

About WSPN

WSPN is a leading provider of next-generation stablecoin infrastructure, committed to building a more secure, efficient, and transparent payment solution for the global economy. Its product portfolio includes stablecoins and a diverse suite of productized solutions for real-world stablecoin payment scenarios, all designed to build and expand the WSPN network ecosystem. Guided by its “Stablecoin 2.0” vision, WSPN places usability, reliability, and accessibility at the core of its approach, driving the mainstream adoption of stablecoins worldwide.

About Aplauz

Aplauz Financial Services Ltd. is a financial technology company that develops and operates platforms and regulatory services enabling partners to build and scale compliant digital payment solutions. Founded in 2020, Aplauz has evolved from a consumer-focused payments provider into a B2B technology and compliance partner.

As part of this strategic transformation, Aplauz has divested its European EMI operations — including Aplauz NL B.V. and previously Aplauz CH GmbH — to focus on delivering technology, licensing, and regulatory infrastructure that empower businesses in the digital payments sector.

‘Blood Moon’ Rises During Total Lunar Eclipse

By
Laotian Times
-
This photograph shows a view of a full moon also known as "Blood Moon" with leaves in the foreground during a phase of a total lunar eclipse in Jakarta on September 8, 2025. Stargazers will have a chance to see a "Blood Moon" on Sunday night during a total lunar eclipse visible across Asia and swathes of Europe and Africa. (Photo by YASUYOSHI CHIBA / AFP)

AFP – Stargazers enjoyed a “Blood Moon” Sunday night during a total lunar eclipse visible across Asia and swathes of Europe and Africa.

When the Sun, Earth and Moon line up, the shadow cast by the planet on its satellite makes it appear an eerie, deep red color that has astounded humans for millennia.

People in Asia, including India and China, were best placed to see Sunday’s total eclipse, which was also be visible on the eastern edge of Africa as well as in western Australia.

Stargazers in Europe and Africa also got a brief chance to see a partial eclipse just as the Moon rose during the early evening, but the Americas missed out.

The Moon appears red during lunar eclipses because the only sunlight reaching it is “reflected and scattered through the Earth’s atmosphere”, said Ryan Milligan, an astrophysicist at Queen’s University Belfast, Northern Ireland.

Blue wavelengths of light are shorter than red ones, so are more easily dispersed as they travel through Earth’s atmosphere, he told AFP.

“That’s what gives the Moon its red, bloody color.”

While special glasses or pinhole projectors are needed to safely observe solar eclipses, all that is required to see a lunar eclipse is clear weather, and being in the right spot.

The last total lunar eclipse was in March this year, while the one before that was in 2022.

A rare total solar eclipse, when the Moon blocks out the light from the Sun, will be visible in a sliver of Europe on August 12, 2026.

Next year’s totality, the first in mainland Europe since 2006, will be visible only in Spain and Iceland, though other countries will be able to see a significant partial eclipse.

In Spain, the totality will be visible in a roughly 160-kilometre (100-mile) band between Madrid and Barcelona, but neither city will see the full phenomenon, Milligan said.

It will be the first total solar eclipse since one swept across North America in April 2024.

© Agence France-Presse

1...2,4982,4992,500...6,460Page 2,499 of 6,460